Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.

Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM

Open source

DOI: 10.3389/fonc.2022.818679
Published: 2022
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2022.818679,
  title = {Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.},
  author = {Hong DS and Butler MO and Pachynski RK and Sullivan R and Kebriaei P and Boross-Harmer S and Ghobadi A and Frigault MJ and Dumbrava EE and Sauer A and Brophy F and Navenot JM and Fayngerts S and Wolchinsky Z and Broad R and Batrakou DG and Wang R and Solis LM and Duose DY and Sanderson JP and Gerry AB and Marks D and Bai J and Norry E and Fracasso PM},
  year = {2022},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2022.818679},
  url = {https://doi.org/10.3389/fonc.2022.818679}
}

RIS

TY  - JOUR
TI  - Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
AU  - Hong DS
AU  - Butler MO
AU  - Pachynski RK
AU  - Sullivan R
AU  - Kebriaei P
AU  - Boross-Harmer S
AU  - Ghobadi A
AU  - Frigault MJ
AU  - Dumbrava EE
AU  - Sauer A
AU  - Brophy F
AU  - Navenot JM
AU  - Fayngerts S
AU  - Wolchinsky Z
AU  - Broad R
AU  - Batrakou DG
AU  - Wang R
AU  - Solis LM
AU  - Duose DY
AU  - Sanderson JP
AU  - Gerry AB
AU  - Marks D
AU  - Bai J
AU  - Norry E
AU  - Fracasso PM
PY  - 2022
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2022.818679
UR  - https://doi.org/10.3389/fonc.2022.818679
ER  -

APA

DS, H., MO, B., RK, P., R, S., P, K., S, B., A, G., MJ, F., EE, D., A, S., F, B., JM, N., S, F., Z, W., R, B., DG, B., R, W., LM, S., DY, D., JP, S., AB, G., D, M., J, B., E, N., & PM, F. (2022). Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.. Frontiers in oncology. https://doi.org/10.3389/fonc.2022.818679

Source records

pubmed · retrieved 2026-09-27T15:28:35.712Z